-
公开(公告)号：US20080274959A1
公开(公告)日：2008-11-06
申请号：US11794068
申请日：2005-12-16
申请人： Bradley A. Haltli , Haiyin He , Ying Huang , Sridhar Krishna Rabindran , Jiang Wu , Min He
发明人： Bradley A. Haltli , Haiyin He , Ying Huang , Sridhar Krishna Rabindran , Jiang Wu , Min He
IPC分类号： A61K38/16 , C07H21/04 , C12N15/63 , C12N1/21 , C12N1/15 , C12P21/00 , C07H17/08 , C07K14/37 , G01N33/566 , C12N1/14 , G01N33/53 , A61P35/00
CPC分类号： C12N15/52
摘要： The present invention provides a chromoprotein produced by Actinomadura sp. 21G792, as well as amino acid and nucleic acid sequences of the apoprotein component of the chromoprotein and of components of the biosynthetic pathway for the chromophore. The present invention is useful for developing pharmaceutical and treating diseases such as cancer or bacterial infections.
摘要翻译： 本发明提供由放线菌属（Actinomadura sp。）生产的色素蛋白 21G792，以及发色蛋白的脱辅基蛋白组分的氨基酸和核酸序列以及发色团的生物合成途径的组分。 本发明可用于开发药物和治疗诸如癌症或细菌感染的疾病。
-
公开(公告)号：US06372775B1
公开(公告)日：2002-04-16
申请号：US09321182
申请日：1999-05-27
IPC分类号： A01N4338
CPC分类号： C07D471/22 , C07D498/22
摘要： The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
摘要翻译： 本发明描述了使用烟曲霉素A，B和C以及一系列式（I）的二酮哌嗪类使多药耐药（MDR）癌细胞对化疗药物的细胞毒性作用进行复敏。
-
公开(公告)号：US06878737B2
公开(公告)日：2005-04-12
申请号：US10086132
申请日：2002-02-28
IPC分类号： C07D471/22 , C07D498/22 , A01N31/40 , A01N43/38 , A01N43/42
CPC分类号： C07D471/22 , C07D498/22
摘要： The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
摘要翻译： 本发明描述了使用烟曲霉素A，B和C以及一系列式（I）的二酮哌嗪类使多药耐药（MDR）癌细胞再次化疗化疗药物的细胞毒性作用。
-
公开(公告)号：US20080319011A1
公开(公告)日：2008-12-25
申请号：US12136357
申请日：2008-06-10
IPC分类号： A61K31/4709 , A61K31/47 , A61P35/00 , A61K31/506
CPC分类号： C04B35/632 , C07D215/54 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
摘要翻译： 本发明提供式1化合物，其具有其中R1，R2，R3，R4和R5在本说明书中描述的结构。
-
公开(公告)号：US07399865B2
公开(公告)日：2008-07-15
申请号：US10939007
申请日：2004-09-10
IPC分类号： C07D215/38
CPC分类号： C04B35/632 , C07D215/54 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
摘要翻译： 本发明提供具有其中R 1，R 2，R 3，R 4，或S >和R 5在说明书中描述。
-
公开(公告)号：US10603314B2
公开(公告)日：2020-03-31
申请号：US11883474
申请日：2006-02-02
申请人： Daniel A. Haber , Daphne Winifred Bell , Jeffrey E. Settleman , Raffaella Sordella , Nadia G. Godin-Heymann , Eunice L. Kwak , Sridhar Krishna Rabindran
发明人： Daniel A. Haber , Daphne Winifred Bell , Jeffrey E. Settleman , Raffaella Sordella , Nadia G. Godin-Heymann , Eunice L. Kwak , Sridhar Krishna Rabindran
IPC分类号： A61K31/4709 , A61K31/4706 , A61K31/17 , A61K38/17
摘要： The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
-
公开(公告)号：US07982043B2
公开(公告)日：2011-07-19
申请号：US12136357
申请日：2008-06-10
IPC分类号： C07D215/38
CPC分类号： C04B35/632 , C07D215/54 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
摘要翻译： 本发明提供式1化合物，其具有其中R1，R2，R3，R4和R5在本说明书中描述的结构。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.035 秒)
